262 related articles for article (PubMed ID: 28219003)
1. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside.
Cho BS; Kim HJ; Konopleva M
Korean J Intern Med; 2017 Mar; 32(2):248-257. PubMed ID: 28219003
[TBL] [Abstract][Full Text] [Related]
2. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
[TBL] [Abstract][Full Text] [Related]
3. A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
Han AR; Lee JY; Kim HJ; Min WS; Park G; Kim SH
Oncol Rep; 2015 Dec; 34(6):2880-8. PubMed ID: 26398122
[TBL] [Abstract][Full Text] [Related]
4. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?
Tavor S; Petit I
Semin Cancer Biol; 2010 Jun; 20(3):178-85. PubMed ID: 20637871
[TBL] [Abstract][Full Text] [Related]
5. Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?
Bernasconi P; Farina M; Boni M; Dambruoso I; Calvello C
Am J Hematol; 2016 May; 91(5):507-17. PubMed ID: 26822317
[TBL] [Abstract][Full Text] [Related]
6. Role of CXCR4 in the pathogenesis of acute myeloid leukemia.
Peled A; Tavor S
Theranostics; 2013; 3(1):34-9. PubMed ID: 23382784
[TBL] [Abstract][Full Text] [Related]
7. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
Tabe Y; Shi YX; Zeng Z; Jin L; Shikami M; Hatanaka Y; Miida T; Hsu FJ; Andreeff M; Konopleva M
PLoS One; 2013; 8(6):e62785. PubMed ID: 23826077
[TBL] [Abstract][Full Text] [Related]
8. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
Zeng Z; Shi YX; Samudio IJ; Wang RY; Ling X; Frolova O; Levis M; Rubin JB; Negrin RR; Estey EH; Konoplev S; Andreeff M; Konopleva M
Blood; 2009 Jun; 113(24):6215-24. PubMed ID: 18955566
[TBL] [Abstract][Full Text] [Related]
9. A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo.
Li X; Guo H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2014 Oct; 4():6610. PubMed ID: 25312253
[TBL] [Abstract][Full Text] [Related]
10. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
Peled A; Klein S; Beider K; Burger JA; Abraham M
Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
[TBL] [Abstract][Full Text] [Related]
11. Targeting the microenvironment in acute myeloid leukemia.
Rashidi A; Uy GL
Curr Hematol Malig Rep; 2015 Jun; 10(2):126-31. PubMed ID: 25921388
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
Zeng Z; Samudio IJ; Munsell M; An J; Huang Z; Estey E; Andreeff M; Konopleva M
Mol Cancer Ther; 2006 Dec; 5(12):3113-21. PubMed ID: 17172414
[TBL] [Abstract][Full Text] [Related]
13. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
[TBL] [Abstract][Full Text] [Related]
14. [CXCR4: a new therapeutic target of the leukaemic cell? Role of the SDF-1/CXCR4 axis in acute myeloid leukaemia].
Tavernier E; Aanei C; Solly F; Flandrin-Gresta P; Campos L; Guyotat D
Bull Cancer; 2014 Jun; 101(6):593-604. PubMed ID: 24977448
[TBL] [Abstract][Full Text] [Related]
15. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia.
Landry B; Gül-Uludağ H; Plianwong S; Kucharski C; Zak Z; Parmar MB; Kutsch O; Jiang H; Brandwein J; Uludağ H
J Control Release; 2016 Feb; 224():8-21. PubMed ID: 26742943
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.
Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T
Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398
[TBL] [Abstract][Full Text] [Related]
17. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model.
Zhang Y; Patel S; Abdelouahab H; Wittner M; Willekens C; Shen S; Betems A; Joulin V; Opolon P; Bawa O; Pasquier F; Ito M; Fujii N; Gonin P; Solary E; Vainchenker W; Coppo P; De Botton S; Louache F
Cell Death Dis; 2012 Oct; 3(10):e396. PubMed ID: 23034331
[TBL] [Abstract][Full Text] [Related]
18. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
Sison EA; McIntyre E; Magoon D; Brown P
Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
[TBL] [Abstract][Full Text] [Related]
19. CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia.
Ramakrishnan R; Peña-Martínez P; Agarwal P; Rodriguez-Zabala M; Chapellier M; Högberg C; Eriksson M; Yudovich D; Shah M; Ehinger M; Nilsson B; Larsson J; Hagström-Andersson A; Ebert BL; Bhatia R; Järås M
Cell Rep; 2020 May; 31(8):107684. PubMed ID: 32460032
[TBL] [Abstract][Full Text] [Related]
20. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers.
Burger JA; Peled A
Leukemia; 2009 Jan; 23(1):43-52. PubMed ID: 18987663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
